A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children

S. McGovern , J. Johnson , D. Luo , K. Nguyen , M. McAleer , A. Paulino , D. Grosshans , P. Baxter , W. Zaky , P. Thall , A. Mahajan
{"title":"A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children","authors":"S. McGovern ,&nbsp;J. Johnson ,&nbsp;D. Luo ,&nbsp;K. Nguyen ,&nbsp;M. McAleer ,&nbsp;A. Paulino ,&nbsp;D. Grosshans ,&nbsp;P. Baxter ,&nbsp;W. Zaky ,&nbsp;P. Thall ,&nbsp;A. Mahajan","doi":"10.1016/j.ijrobp.2024.11.049","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Reirradiation is increasingly considered for recurrent pediatric brain tumors, but dosimetric guidelines are lacking. To identify composite dose-volume constraints for reirradiation of recurrent brain tumors in children, a prospective trial was conducted.</div></div><div><h3>Methods</h3><div>Nine children with recurrent brain tumors previously treated with radiation were prospectively reirradiated. Three had GBM, two had AT/RT, and one each had ependymoma, NGGCT, medulloblastoma, or meningioma. For all patients, DICOM format records of their prior radiation (RT1) fields were obtained and deformed onto the CT simulation for their second course of radiation (RT2). Conventionally fractionated treatment plans for RT2 satisfied dose constraints for RT2 alone and the composite sum of both courses (RT1+RT2). The primary endpoint was the rate of symptomatic brain necrosis at 6 months after RT2.</div></div><div><h3>Results</h3><div>Median age at RT2 was 9.7y (range, 2.9 -6.8 y). Median interval between RT1 and RT2 was 19 months (range, 7–82 months). Treatment modality for RT2 was VMAT for seven patients and proton therapy for two patients. Median prescription dose for RT2 was 45 Gy (range, 30.6-60 Gy). Five patients were evaluable for the primary endpoint; none had symptomatic brain necrosis at 6 months after RT2. Four patients were not evaluble at 6 months due to death (n=2) or transition to hospice (n=2) by 6 months, all due to progression of disease. Median overall survival from RT2 start for all patients was 10.7 months (range, 5.2-46.4 months).</div></div><div><h3>Conclusions</h3><div>This prospective study suggests that conventionally fractionated reirradiation for recurrent brain tumors in children may be performed safely. These results provide a starting point for development of dose-volume constraints for pediatric brain reirradiation. Advanced technologies such as proton therapy may allow for reirradiation dose escalation while minimizing dose to surrounding critical structures.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"121 3","pages":"Pages e13-e14"},"PeriodicalIF":6.4000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S036030162403623X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Reirradiation is increasingly considered for recurrent pediatric brain tumors, but dosimetric guidelines are lacking. To identify composite dose-volume constraints for reirradiation of recurrent brain tumors in children, a prospective trial was conducted.

Methods

Nine children with recurrent brain tumors previously treated with radiation were prospectively reirradiated. Three had GBM, two had AT/RT, and one each had ependymoma, NGGCT, medulloblastoma, or meningioma. For all patients, DICOM format records of their prior radiation (RT1) fields were obtained and deformed onto the CT simulation for their second course of radiation (RT2). Conventionally fractionated treatment plans for RT2 satisfied dose constraints for RT2 alone and the composite sum of both courses (RT1+RT2). The primary endpoint was the rate of symptomatic brain necrosis at 6 months after RT2.

Results

Median age at RT2 was 9.7y (range, 2.9 -6.8 y). Median interval between RT1 and RT2 was 19 months (range, 7–82 months). Treatment modality for RT2 was VMAT for seven patients and proton therapy for two patients. Median prescription dose for RT2 was 45 Gy (range, 30.6-60 Gy). Five patients were evaluable for the primary endpoint; none had symptomatic brain necrosis at 6 months after RT2. Four patients were not evaluble at 6 months due to death (n=2) or transition to hospice (n=2) by 6 months, all due to progression of disease. Median overall survival from RT2 start for all patients was 10.7 months (range, 5.2-46.4 months).

Conclusions

This prospective study suggests that conventionally fractionated reirradiation for recurrent brain tumors in children may be performed safely. These results provide a starting point for development of dose-volume constraints for pediatric brain reirradiation. Advanced technologies such as proton therapy may allow for reirradiation dose escalation while minimizing dose to surrounding critical structures.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
期刊最新文献
Moving from the background towards the spotlight: A critical review of radiation therapy for locally advanced pancreas cancer. A Pilot Study of CT Simulator Downtime at an African Cancer Conference: Survey Results from AORTIC 2023. Regional Near-surface Dose Predicts Moist Desquamation and Implant Failure in Patients Receiving Radiation Therapy for Breast Cancer. Boswellia serrata for cerebral radiation necrosis after radiosurgery for brain metastases. Development and validation of a prediction model for cardiac events in patients with hepatocellular carcinoma undergoing stereotactic body radiation therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1